Eagle Pharmaceuticals Stock Fundamentals
| EGRXDelisted Stock | USD 1.99 0.02 1.02% |
Eagle Pharmaceuticals fundamentals help investors to digest information that contributes to Eagle Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eagle Pink Sheet. The fundamental analysis module provides a way to measure Eagle Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eagle Pharmaceuticals pink sheet.
Eagle |
Eagle Pharmaceuticals Company Operating Margin Analysis
Eagle Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Eagle Pharmaceuticals Operating Margin | 0.16 % |
Most of Eagle Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eagle Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Eagle Pharmaceuticals has an Operating Margin of 0.1594%. This is 100.45% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 102.89% lower than that of the firm.
Eagle Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eagle Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Eagle Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eagle Pharmaceuticals competition to find correlations between indicators driving Eagle Pharmaceuticals's intrinsic value. More Info.Eagle Pharmaceuticals is rated below average in return on equity category among its peers. It is one of the top stocks in return on asset category among its peers reporting about 1.36 of Return On Asset per Return On Equity. Comparative valuation analysis is a catch-all model that can be used if you cannot value Eagle Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eagle Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Eagle Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eagle Pharmaceuticals' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eagle Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eagle Pharmaceuticals by comparing valuation metrics of similar companies.Eagle Pharmaceuticals is currently under evaluation in operating margin category among its peers.
Eagle Fundamentals
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 82.05 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 76.65 % | ||||
| Number Of Shares Shorted | 350.53 K | ||||
| Price To Earning | 40.52 X | ||||
| Price To Book | 0.10 X | ||||
| Price To Sales | 0.11 X | ||||
| Revenue | 316.61 M | ||||
| Gross Profit | 221.67 M | ||||
| EBITDA | 65.48 M | ||||
| Net Income | (2.67 M) | ||||
| Cash And Equivalents | 36.56 M | ||||
| Cash Per Share | 2.75 X | ||||
| Total Debt | 62.47 M | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 1.78 X | ||||
| Book Value Per Share | 19.25 X | ||||
| Cash Flow From Operations | 30.8 M | ||||
| Short Ratio | 3.91 X | ||||
| Earnings Per Share | 0.85 X | ||||
| Price To Earnings To Growth | 0.91 X | ||||
| Target Price | 17.0 | ||||
| Number Of Employees | 134 | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 27.73 M | ||||
| Total Asset | 406.16 M | ||||
| Retained Earnings | 111.5 M | ||||
| Working Capital | 77.67 M | ||||
| Current Asset | 119.05 M | ||||
| Current Liabilities | 35.45 M | ||||
| Net Asset | 406.16 M |
About Eagle Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eagle Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eagle Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eagle Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. Eagle Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |